Hypera SA
BOVESPA:HYPE3

Watchlist Manager
Hypera SA Logo
Hypera SA
BOVESPA:HYPE3
Watchlist
Price: 23.15 BRL -2.16% Market Closed
Market Cap: 14.7B BRL

Profitability Summary

Hypera SA's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Hypera SA

Revenue
7B BRL
Cost of Revenue
-3B BRL
Gross Profit
4B BRL
Operating Expenses
-2.8B BRL
Operating Income
1.2B BRL
Other Expenses
-326.6m BRL
Net Income
823.9m BRL

Margins Comparison
Hypera SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
BR
Hypera SA
BOVESPA:HYPE3
14.7B BRL
57%
17%
12%
US
Eli Lilly and Co
NYSE:LLY
1T USD
83%
44%
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
495.1B USD
68%
27%
27%
CH
Roche Holding AG
SIX:ROG
271.3B CHF
74%
34%
15%
UK
AstraZeneca PLC
LSE:AZN
218.9B GBP
82%
24%
16%
US
Merck & Co Inc
NYSE:MRK
276.1B USD
79%
38%
30%
CH
Novartis AG
SIX:NOVN
218.1B CHF
76%
33%
26%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
82%
42%
33%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
143.8B USD
75%
29%
16%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Hypera SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
BR
Hypera SA
BOVESPA:HYPE3
14.7B BRL
7%
3%
6%
14%
US
Eli Lilly and Co
NYSE:LLY
1T USD
97%
19%
42%
25%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
495.1B USD
33%
13%
18%
13%
CH
Roche Holding AG
SIX:ROG
271.3B CHF
33%
10%
31%
19%
UK
AstraZeneca PLC
LSE:AZN
218.9B GBP
22%
9%
18%
15%
US
Merck & Co Inc
NYSE:MRK
276.1B USD
40%
15%
26%
21%
CH
Novartis AG
SIX:NOVN
218.1B CHF
33%
14%
25%
18%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
71%
23%
57%
28%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
143.8B USD
11%
5%
11%
10%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less